29044-26-6

Usage

Uses

Used in Pharmaceutical Industry:
N-HYDROXY-4-MORPHOLINECARBOXIMIDAMIDE is used as a reactive intermediate in the synthesis of various pharmaceuticals for its ability to form stable amide bonds with primary amines, aiding in the development of new drugs and improving drug delivery.
Used in Agrochemical Industry:
N-HYDROXY-4-MORPHOLINECARBOXIMIDAMIDE is used as a component in the synthesis of agrochemicals to enhance the effectiveness of pesticides and other agricultural products by forming stable bonds with target molecules.
Used in Dye Production:
N-HYDROXY-4-MORPHOLINECARBOXIMIDAMIDE is used in the production of certain dyes to improve their stability and performance characteristics through the formation of amide bonds.
Used in Rubber and Plastic Industry:
N-HYDROXY-4-MORPHOLINECARBOXIMIDAMIDE is used in the production of certain rubber and plastic products to enhance their properties, such as durability and flexibility, through stable amide bond formation.
Used in Bioconjugation:
N-HYDROXY-4-MORPHOLINECARBOXIMIDAMIDE is used as a key component in the covalent conjugation of ligands to proteins, enabling the attachment of various molecules to proteins for applications in research, diagnostics, and therapeutics.
Used in Surface Modification:
N-HYDROXY-4-MORPHOLINECARBOXIMIDAMIDE is used in the surface modification of materials for applications in biomedical research and diagnostics, allowing for the attachment of specific functional groups to enhance material properties and interactions with biological systems.

Upstream product

• 1530-89-8 N-cyanomorpholine 

Downstream Products

• 1426133-38-1 N-(2-methyl-5-(3-morpholino-1,2,4-oxadiazol-5-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 115983-45-4 7-Chlor-3-morpholinopyridazino<4,3-f>-1,2,4-oxadiazepin-5(2H)-on 

Relevant academic research and scientific papers

Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4- methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases

Class I phosphoinositide 3-kinases (PI3Ks), particularly PI3Kγ, have become attractive drug targets for inflammatory and autoimmune disorders such as rheumatoid arthritis. Herein, we describe the synthesis and the structure-activity relationships (SAR) of a series of 2-amino-5-oxadiazolyl thiazoles, culminating in the identification of 8j (TASP0415914), an orally potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ). TASP0415914 demonstrated good potency in a cell-based assay and, furthermore, exhibited in vivo efficacy in a collagen induced arthritis (CIA) model in mice after oral administration.

AMINOTHIAZOLE DERIVATIVE

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase 3 inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn''s disease, irritable colitis, Sjoegren''s syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES

Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof

Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, R2, A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders

Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.

Isoform-selective substrates of nitric oxide synthase

Because of the double-edged nature of NO, the development of isoform-selective NOS substrates is a highly desirable goal. Given the striking similarity in the heme active sites of the three NOS isoforms, it presents an challenging problem. Several N-aryl-N′-hydroxyguanidines have recently been shown as substrates that are selective for iNOS over nNOS. Here, we report the first success that 3 is a good substrate for nNOS (70% activity of NOHA, Km ≈ 40 ± 6 μM) over iNOS.

Novel Fused N-Heterocycles Derived from 3,6-Dichloro-4-pyridazinecarbonyl Chloride

3,6-Dichloro-4-pyridazinecarbonyl chloride (4) reacts with primary amines to yield the N-containing fused heterocyclic compounds 2, 8, and 9a, b. 4 forms the pyridazino-oxadiazepines 7a-d with the in situ generated hydroxyguanidines 6a-d.The diazocinedione 1 is obtained by reaction of 3,6-dichloro-4-pyridazinecarboxamide (3) with anthranilic acid methyl ester.